SCHEMBL13289243

SCHEMBL13289243

Bc1cnn2c(NCCCCNS(=O)(=O)c3ccc(Cl)cc3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 4/20 0.46
▸ CDK2 P24941 4/20 0.44
▸ MAPT P10636 4/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ CYP2D6 P10635 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ TP53 P04637 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ KDM4E B2RXH2 3/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ CCR6 P51684 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ GSR P00390 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13289474 0.98 GSK3B (0.46) GSK3BCDK2MAPTALDH1A1CYP1A2
SCHEMBL13289057 0.95 GSK3B (0.46) GSK3BCDK2MAPTALDH1A1CYP1A2
SCHEMBL13289270 0.95 CDK2 (0.46) GSK3BCDK2MAPTALDH1A1CYP1A2
SCHEMBL13289033 0.93 GSK3B (0.45) GSK3BCDK2MAPTALDH1A1CYP1A2
SCHEMBL13289514 0.93 GSK3B (0.55) GSK3BCDK2MAPTALDH1A1CYP1A2
SCHEMBL13288972 0.93 CDK2 (0.44) GSK3BCDK2MAPTALDH1A1CYP1A2
SCHEMBL13289252 0.92 GSK3B (0.46) GSK3BCDK2MAPTALDH1A1CYP1A2
SCHEMBL13289029 0.91 GSK3B (0.47) GSK3BCDK2MAPTALDH1A1CYP1A2
SCHEMBL12954453 0.91 CDK2 (0.44) GSK3BCDK2MAPTALDH1A1CYP1A2
SCHEMBL13289501 0.91 ALDH1A1 (0.47) GSK3BCDK2ALDH1A1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback